Joincare Pharmaceutical Group Industry Co., Ltd. Class ASSE: 600380

Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint

· Issued by Joincare Pharmaceutical Group Industry Co., Ltd. Class A via Shanghai Stock Exchange
Indicative Announcement on the Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection Reaching the Primary Study Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis